Ovid Therapeutics (OVID) Enterprise Value (2016 - 2026)

Ovid Therapeutics has reported Enterprise Value for 11 years, with the latest figure at -$155.5 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 261.71% year-over-year to -$155.5 million; the trailing twelve-month figure through Mar 2026 stood at -$155.5 million (down 261.71% YoY), and the FY2025 full-year result was -$69.1 million, down 30.23% from the prior year.
• Enterprise Value for Q1 2026 stood at -$155.5 million, down from -$69.1 million in the prior quarter.
• The five-year high for Enterprise Value was -$25.5 million in Q3 2025, with the low at -$166.7 million in Q1 2022.
• Historically, Enterprise Value has averaged -$93.7 million across 5 years, with a median of -$88.9 million in 2024.
• Annual changes were most pronounced in 2025 — Enterprise Value soared 59.61% — and 2026, when it tumbled 261.71%.
• Ovid Therapeutics' Enterprise Value stood at -$126.1 million in 2022, then climbed by 16.1% to -$105.8 million in 2023, then surged by 49.85% to -$53.1 million in 2024, then slumped by 30.23% to -$69.1 million in 2025, then sank by 125.01% to -$155.5 million in 2026.
• The last three Enterprise Value figures came in at -$155.5 million (Q1 2026), -$69.1 million (Q4 2025), and -$25.5 million (Q3 2025), per Business Quant data.